



## CO-FOUNDER NEEDED

# Turning catheter infections into life-saving warnings

## PathoVigil



### THE PROBLEM

Over 160,000 central venous catheter (CVC) infections occur annually in Europe, leading to ~25,000 preventable deaths due to delayed detection. Existing diagnostics are invasive, slow, and reactive, missing the critical early window, extending hospital stays, and driving billions in avoidable costs.

### OUR SOLUTION

A compact wearable platform combining bioimpedance and optical sensing for non-invasive monitoring at the CVC site, detecting infection before symptoms appear. Enabling earlier intervention, reduced complications, and lower costs. Built to expand into high-need areas like sarcopenia and diabetic foot care.

### PATENT STATUS

IP strategy in preparation.

### FINANCIAL OVERVIEW

Scalable B2B model: hardware sales + high-margin recurring SaaS for monitoring. Targeting a multi-billion-euro infection prevention market with strong unit economics and expansion into chronic care.

### MILESTONES

**Achieved:** Ethical approval and partnership with Odense University Hospital (OUH).

**Next:** OUH clinical testing launch, product development, TRL 6-7 advancement, IP/CE prep, spin-out and seed funding.

### TARGET MARKET & CUSTOMERS

Hospitals and ICUs with high-volume CVC patients in critical/oncology care, expanding to home-care and chronic providers for diabetes/sarcopenia, Europe-first infection control opportunity with global upside.

### CO-FOUNDER PROFILE WE ARE LOOKING FOR

#### Preferred qualifications

- MedTech regulatory and commercialization experience (EU frameworks, clinical validation, market access)
- Strong hospital networks + B2B go-to-market in healthcare/diagnostics
- Fundraising across non-dilutive and private capital (grants, angels, VCs)
- Solid understanding of medical devices, sensing technologies, and applied electronics

#### Personal fit

Mission-driven builder who excels in spin-out uncertainty, executes strategically, embraces high-reward risk for life-saving impact, and commits long-term to patient-first values and venture growth.

### TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Drive commercial strategy alongside clinical activities. Lead go-to-market direction, expand partnerships through clinical networks, advance investor readiness, and contribute to product development.

### ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

**Mahdi Momeni**, PhD in Biomedical Eng.

**Daniel Teichmann**, (Prof.) PhD in Biomedical Engineering.



**Bo Nilsson**, Business Developer.

**Jeyapiravinah Kugan**, MedTech Business Developer.


### PHYSICAL ADDRESS

Odense, University of Southern Denmark

[mome@mmpi.sdu.dk](mailto:mome@mmpi.sdu.dk)



CVC exit-site



CVC exit site skin infections

**References**  
[1] TheFreeDictionary's Medical dictionary  
[2] <https://nepshim.com/>  
[3] Cesaro, Simone, Maria Cavallero, Anna Peggareo, Piergiorgio Gamba, Nicola Zadra, and Gloria Tridello. "A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients." *Annals of hematology* 95 (2016): 817-825.



### ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

[www.open-entrepreneurship.com](https://www.open-entrepreneurship.com)

SUPPORTED BY



**Uddannelses- og Forskningsministeriet**